Drug Profile
Research programme: cyclocreatine - Lumos Pharma
Alternative Names: CincY; Cyclocreatine - Lumos Pharma; LUM-001 - Lumos Pharma; UNII-6732XGX1RKLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator University of Cincinnati
- Developer Lumos Pharma
- Class Amino acids; Anti-ischaemics; Antineoplastics; Antivirals; Imidazolidines; Small molecules
- Mechanism of Action Creatine replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported X-linked creatine deficiency
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in X-linked-creatine-deficiency in USA (PO)
- 18 Jun 2012 Lumos Pharma's cyclocreatine receives Orphan Drug status for X-linked-genetic-disorders in USA
- 07 Feb 2012 Preclinical trials in X-linked creatine deficiency in USA (PO)